RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6 inhibitor G1T28 for patients with small-cell lung cancer (SCLC) will be presented at the International Association for the Study of Lung Cancer’s 17th World Conference on Lung Cancer (WCLC), to be held December 4 – 7 at the Messe Wien Exhibition & Congress Center in Vienna, Austria. Details on the poster are as follows:

Title: G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Poster Session: PS01
Poster Number: P1.07-002
Date / Time: Monday, December 5, 2:30 p.m. – 3:45 p.m. CET
Location: Hall B of the Messe Wien Exhibition & Congress Center
Presenter: Lowell L. Hart, M.D., Florida Cancer Specialists, Fort Myers, FL

G1 will also present preclinical data on G1T28 in a poster session at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium, to be held November 29 – December 2 at the Internationales Congress Center Munich in Munich, Germany. Details on the poster are as follows:

Title: G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
Poster Session: Molecular targeted agents II
Poster Number: P118
Date / Time: Thursday, December 1, 10:15 a.m. – 5 p.m. CET
Location: The Exhibition Hall of Internationales Congress Center Munich
Presenter: Patrick J. Roberts, Ph.D., Pharm.D., Director of Translational Medicine, G1 Therapeutics

About G1T28

G1T28 is a potential first-in-class, short-acting IV CDK4/6 inhibitor being developed to preserve hematopoietic stem cells and enhance immune system function during chemotherapy. G1T28 is being studied in two Phase 1b/2a proof-of-concept trials in patients with small-cell lung cancer: a study in newly diagnosed, treatment-naive patients (NCT02499770), and a study in previously treated patients (NCT02514447).

About G1 Therapeutics, Inc.

G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in people with cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.

Visit www.g1therapeutics.com for more information.

Contact:                                                               
Mark Velleca, MD, PhD                 
G1 Therapeutics                                               
919-213-9838                                                     
mvelleca@g1therapeutics.com                 

Media:
Laura Bagby                      
6 Degrees Communications
312-448-8098
lbagby@6degreespr.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.